BGBC016 STK11 NSCLC (Non-Small Cell Lung Cancer) - Clinical Trial
What is the Purpose of this Study?
We are doing this study to find out if an investigational drug called bemcentinib (the study drug) is a safe and effective option when it is combined with the standard therapy for non-small cell lung cancer (1 immunotherapy drug and 2 chemotherapy drugs).
What is the Condition Being Studied?
Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Who Can Participate in the Study?
Adults ages 18+ who are diagnosed with advanced non-squamous non-small cell lung cancer.
For more information about who can be in this study, please contact the study team at annmarie.peters@duke.edu.
Age Group
Adults
What is Involved?
If you join this study, you will go through a screening period to make sure you are eligible. During the screening period you will:
- Have blood draws
- Have imaging scans (CT and MRI)
- Have 2 procedures to check your heart function, an electrocardiogram (ECG) and either an echocardiogram (ECHO) or a multigated acquisition scan (MUGA)
If you are eligible to get the study drug, you will:
Study Details
Full Title
Phase 1b/2a safety and tolerability study of bemcentinib with pembrolizumab/carboplatin/pemetrexed in subjects with untreated advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) without/with a STK11 mutation. (BGBC016 STK11 NSCLC)
Principal Investigator
Medical Oncologist
Protocol Number
IRB:
PRO00112972
NCT:
NCT05469178
Phase
Phase
I/II
ClinicalTrials.gov
View on ClinicalTrials.gov
Enrollment Status
Open for Enrollment